je.st
news
Tag: idec
Biogen Idec shortens its name to Biogen
2015-03-23 15:31:48| Biotech - Topix.net
It said the moves reflects both its evolution and focus on bringing forth new therapies in areas of high unmet need while honoring its legacy as a pioneer in the biotechnology industry. The company was created 12 years ago through the merger of Biogen with IDEC Pharmaceuticals and has since focused on three core areas, including neurology, immunology and hematology.
Biogen Idec and Sobi Announce Positive Top-Line Efficacy and Safety...
2015-02-27 16:20:00| Appliances - Topix.net
CAMBRIDGE, Mass. & STOCKHOLM-- -- Biogen Idec and Swedish Orphan Biovitrum AB today announced positive top-line results of the Kids B-LONG Phase 3 clinical study that evaluated the safety, efficacy and pharmacokinetics of ALPROLIXA [Coagulation Factor IX , Fc Fusion Protein] in children under age 12 with severe hemophilia B. ALPROLIX was generally well tolerated and no inhibitors were detected during the study.
Tags: positive
safety
announce
efficacy
IDEC Introduces FT1A Touch 14 I/O
2014-11-11 14:58:12| Chemical Processing
IDEC introduced a new model in its FT1A Touch micro programmable controller series of combo HMI+PLC units, the FT1A Touch 14 I/O.
Tags: touch
io
introduces
idec
Biogen Idec And Swedish Orphan Biovitrum Announce European Medicines...
2014-11-04 04:36:32| Appliances - Topix.net
CAMBRIDGE, Mass. & STOCKHOLM-- --Biogen Idec and Swedish Orphan Biovitrum AB today announced that the European Medicines Agency has validated the Marketing Authorization Application of ELOCTATM , a recombinant factor VIII Fc fusion protein product candidate for the treatment of hemophilia A. The validation of the MAA initiates the EMA's review process.
Tags: european
swedish
announce
medicines
Biogen Idec and Sobi Announce European Medicines Agency Validates...
2014-10-31 22:14:45| Appliances - Topix.net
CAMBRIDGE, Mass. & STOCKHOLM-- -- Biogen Idec and Swedish Orphan Biovitrum AB today announced that the European Medicines Agency has validated the Marketing Authorization Application of ELOCTAa , a recombinant factor VIII Fc fusion protein product candidate for the treatment of hemophilia A. The validation of the MAA initiates the EMA's review process.
Tags: agency
european
announce
medicines